In this Phase III , multicenter , parallel-group , double-blind study , drug-naive patients with glycosylated hemoglobin ( HbA1c ) levels 7.0 % to 10.5 % ( 53-91 mmol/mol ) were randomized ( by using an interactive voice response system ) to receive placebo ( n = 132 ) , dapagliflozin 5 mg ( n = 128 ) , or dapagliflozin 10 mg ( n = 133 ) .